Exelixis Stock - weekly review and biotech sector context
19.06.2026 - 22:46:53 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:40 UTC. Details in the imprint.
Exelixis (US30161Q1040) is ending the week after a solid year-to-date advance, with shares consolidating near recent levels on the Nasdaq. The oncology-focused biotech has benefited from stable Cabometyx revenues and ongoing pipeline expectations among investors.
All news and data on Exelixis stock
Further company announcements, filings and quote data for Exelixis can be found in our dedicated topic area and on the company’s Investor Relations site.
What this week shows for Exelixis
Exelixis shares trade around the low-$50s, with MarketBeat citing a last regular-session close of $51.91 on 06/18/2026, after an 18.4% gain from $43.83 at the start of the year. MarketBeat data on Exelixis
The move leaves the stock not far from its 12-month highs, while still within a valuation range many analysts see as consistent with its mature lead asset and late-stage pipeline. Trading volumes this week have been in line with recent averages.
Biotech sector backdrop and peers
The broader US biotech space remains mixed, with smaller development-stage names volatile and larger profitable players such as Exelixis showing more stable trends. The iShares Biotechnology ETF has seen only muted moves in recent sessions, reflecting this balance.
Against this backdrop, Exelixis stands out as a mid-cap oncology name with positive earnings and cash generation, contrasting with many loss-making peers. That profile can matter for investors comparing risk levels within the biotech segment.
The product behind the stock
Exelixis generates the bulk of its revenue from Cabometyx, a tablet formulation of cabozantinib used to treat certain kidney and liver cancers, marketed in the United States in partnership structures and via licenses abroad. Exelixis company overview
Where the stock trades today
Exelixis shares (US30161Q1040) trade on the Nasdaq at $51.91 as of 06/18/2026, 16:00 Eastern Time.
Exelixis at a glance
- Company: Exelixis Inc.
- ISIN: US30161Q1040
- WKN: 936718
- Ticker: EXEL
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 Eastern Time): 51.91 USD
- Market cap: approximately 16.5 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
